NCT00057915View on ClinicalTrials.gov

Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

September 30, 2003

Primary Completion Date

August 31, 2006

Study Completion Date

September 30, 2006

Conditions
Unspecified Adult Solid Tumor, Protocol Specific
Interventions
BIOLOGICAL

CEA peptide 1-6D

CAP-1(6D) peptide-pulsed, matured, autologous human DC produced by the AastromReplicell™ Cell Production System

Trial Locations (1)

27705

Duke Comprehensive Cancer Center, Durham

Sponsors

Lead Sponsor

Duke University
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Duke University

OTHER

NCT00057915 - Vaccine Therapy in Treating Patients With Refractory Stage IV Cancer | Biotech Hunter | Biotech Hunter